Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxifloxacin + nitazoxanide + omeprazole + doxycycline
- Development stage
- Unknown
- Lead developer
- Sherief Abd-Elsalam
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This quadruple therapy is an experimental treatment regimen for Helicobacter pylori infection, developed and studied by Sherief Abd-Elsalam. It consists of a combination of the fluoroquinolone antibiotic moxifloxacin, the antiprotozoal agent nitazoxanide, the proton pump inhibitor omeprazole (formulated with sodium bicarbonate), and the tetracycline antibiotic doxycycline. This regimen was designed to overcome the increasing resistance of H. pylori to standard triple therapies. Moxifloxacin and doxycycline provide broad-spectrum antibacterial activity by inhibiting DNA replication and protein synthesis, respectively. Nitazoxanide targets the anaerobic metabolism of the bacteria by interfering with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme, while omeprazole reduces gastric acidity to enhance the stability and efficacy of the antibiotics.
- Other names
- Unique Quadruple RegimenMoxifloxacin-based quadruple therapy (Abd-Elsalam)
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)PFOR (Pyruvate:ferredoxin oxidoreductase)Bacterial RibosomeDNA gyraseTopo IV (Bacterial Topoisomerase IV)
Beyond the preview
Go deeper on moxifloxacin + nitazoxanide + omeprazole + doxycycline.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxifloxacin + nitazoxanide + omeprazole + doxycycline.